Cohen Capital Management Inc. Purchases 3,897 Shares of Zoetis Inc. $ZTS

Cohen Capital Management Inc. increased its holdings in Zoetis Inc. (NYSE:ZTS) by 30.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,749 shares of the company’s stock after acquiring an additional 3,897 shares during the period. Cohen Capital Management Inc.’s holdings in Zoetis were worth $2,451,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Nova Wealth Management Inc. bought a new position in Zoetis in the 1st quarter valued at $25,000. Halbert Hargrove Global Advisors LLC boosted its holdings in shares of Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the last quarter. REAP Financial Group LLC grew its position in Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the period. NewSquare Capital LLC increased its holdings in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after buying an additional 85 shares during the last quarter. Finally, 1248 Management LLC bought a new stake in Zoetis in the first quarter worth about $35,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $129.41 on Tuesday. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.40. The stock’s 50-day simple moving average is $124.66 and its 200 day simple moving average is $141.33. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The stock has a market capitalization of $57.03 billion, a price-to-earnings ratio of 21.79, a price-to-earnings-growth ratio of 2.57 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the prior year, the business posted $1.58 earnings per share. The company’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is 35.69%.

Analyst Ratings Changes

ZTS has been the subject of a number of research reports. BTIG Research reissued a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Morgan Stanley set a $160.00 price objective on Zoetis in a report on Thursday, December 18th. JPMorgan Chase & Co. decreased their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Zoetis in a research report on Monday, December 29th. Finally, Argus reiterated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.